Terms: = Thyroid cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
246 results:
1. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
2. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
Ma J; Xu J; Zhang X; Quan J
Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
[TBL] [Abstract] [Full Text] [Related]
3. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
4. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
5. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the pi3k/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
6. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
7. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the Therapeutic Effects of Harmine on Anaplastic thyroid cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract] [Full Text] [Related]
9. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
10. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
11. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract] [Full Text] [Related]
12. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic thyroid cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract] [Full Text] [Related]
13. Oncogenic pik3ca recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway.
Li X; Chen G; Wang F; Guo X; Zhang R; Liu P; Dong L; Yu W; Wang H; Wang H; Yu J
Clin Transl Med; 2023 Nov; 13(11):e1483. PubMed ID: 37965796
[TBL] [Abstract] [Full Text] [Related]
14. USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting pi3k/AKT pathway.
Sun J; Xiang Q; Ding D; Yan N
J Bioenerg Biomembr; 2023 Dec; 55(6):457-466. PubMed ID: 37919637
[TBL] [Abstract] [Full Text] [Related]
15. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract] [Full Text] [Related]
16. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract] [Full Text] [Related]
17. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.
Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597
[TBL] [Abstract] [Full Text] [Related]
18. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
19. Study of the pi3k/Akt/mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.
Liu X; Liu J; Yan B; Quan Z; Wang X; Ma Y; Alarfaj AA; Yan L
Environ Toxicol; 2024 Jan; 39(1):444-456. PubMed ID: 37792628
[TBL] [Abstract] [Full Text] [Related]
20. Methylation-Mediated Silencing of ATF3 Promotes thyroid cancer Progression by Regulating Prognostic Genes in the MAPK and pi3k/AKT Pathways.
Xiao X; Chen M; Sang Y; Xue J; Jiang K; Chen Y; Zhang L; Yu S; Lv W; Li Y; Liu R; Xiao H
Thyroid; 2023 Dec; 33(12):1441-1454. PubMed ID: 37742107
[No Abstract] [Full Text] [Related]
[Next]
